Sanofi

Kidney disease shaped Peio's childhood, but it never defined him. Today, he's still riding forward, mile after mile. Peio’s resilience and the support of the community around him reminds us why we do what we do. Learn more about how we’re chasing the miracles of science so people like Peio can chase their dreams: http://spkl.io/60437TkVN #FutureOfMedicine #ScienceForLife #EmpoweredByScience #ChasingMiracles

One of the most important shifts in oncology is the move toward more precise approaches to immunotherapy. Conditional antibody technologies are designed to activate preferentially in the tumor microenvironment while limiting unwanted effects on normal tissues. In the latest episode of our Partner Spotlight series, Zandra Klippel, Therapeutic Area Head, Oncology Development at Sanofi, sits down with Peter Luo, Co-founder, CEO and President of Adagene, to discuss the potential of conditional antibodies, the role of the tumor microenvironment and how collaboration can help advance increasingly complex oncology science. Check out the full conversation to learn more: http://spkl.io/60467rn8M

🎬 Legacy isn't about looking back. It's about building what's next. Making It Real, Episode 3 is now live. Go inside Sanofi's Toronto site to see how teams are continuously preparing for the future, not with buzzwords, but with action: - Rethinking water and energy management - Enabling career mobility across the site - Driving digital transformation on the floor The insight? Lasting transformation happens when people evolve alongside the business. ▶ Watch the full episode now: http://spkl.io/60407Rkgu #ManufacturingExcellence #ContinuousImprovement #MakingItReal #SanofiStories

A prescription is just the beginning. Patients often face unanswered questions, complex administrative processes, and delays in accessing support, even after that critical moment. This is where digital and AI step in. Not to replace care, but to simplify it. At Sanofi, we're rethinking the patient journey in phases: - Surface signals and risks earlier - Anticipating obstacles and connect information - Enabling smarter, faster decisions The goal is a more connected healthcare system that works better, for the people living through it, from patients to the teams supporting them. Discover how digital and AI are transforming patient care at every step: http://spkl.io/60497ucEt #AIinHealthcare #PatientCare #DigitalHealth #HealthTech

🎬 Legacy is not a contradiction. It's a continuity. What does that mean for a biopharma manufacturing site? At Sanofi's Toronto site, transformation is a continuous journey. It means building more than a century of expertise while never standing still on what's next. ➡️ See it in action: Making it Real Episode 3 live September 9, 2026. #ManufacturingExcellence #ContinuousImprovement #MakingItReal #SanofiStories

Did you know that in autoimmune type 1 diabetes, a confused immune system attacks insulin-producing cells? See how we’re chasing the miracles of science in #aT1D: http://spkl.io/60407uG5j #aT1D #PatientFirst #ChasingMiracles

Today, we’re proud to welcome Sanofi’s new Executive Committee, led by Belén Garijo. A team bringing together diverse expertise and experiences, united by a shared vision for what comes next. 🟣 Manuela Buxo, EVP, Head of Specialty Care 🟣 Paulo Fontoura, EVP, Head of Research and Development 🟣 Thomas Grenier, EVP, General Medicines 🟣 Jamie Haney, EVP, General Counsel 🟣 Veronique JAILLET, Interim Chief People Officer 🟣 Brendan O'Callaghan, EVP, Manufacturing and Supply 🟣 François-Xavier Roger, EVP, Chief Financial Officer 🟣 Thomas Triomphe, EVP, Vaccines This marks the beginning of a new chapter. And there’s plenty more to discover along the way. Welcome to our new Executive Committee! Learn more about the team: http://spkl.io/60477uHuU

Europe's competitiveness in life sciences cannot be taken for granted. This week, our Country Lead Odd A. Gabriel Johannessen took part in an important dialogue at the Confederation of Danish Industry (Dansk Industri) with Ditte Juul Jørgensen, Director-General at the European Commission, and leaders from the life science industry, on Europe's competitiveness, innovation, and the shifting global trade policy landscape. The discussion emphasized how closely trade policy, industrial policy, and health policy are intertwined, and how crucial it is to build strong frameworks for innovation, investment, and fast patient access to new treatments. Thank you to DI Life Science, Ditte Juul Jørgensen, and the other participants for an open and forward-looking dialogue about Europe's future position as a global life science hub.

This year marks 35 years of our humanitarian commitment in rare diseases — more than three decades of standing alongside patients and families around the world. In that time, our Rare Humanitarian Program has helped improve the lives and health of thousands of people around the world by providing access to care based on demonstrated medical need, regardless of where they live or their ability to pay. The Rare Humanitarian Program is an integral part of our work to support sustainable access to care through a comprehensive approach that includes support for diagnosis, treatment, and monitoring across the patient journey. Because of this, more of life's moments are possible. Learn more: http://spkl.io/6047739fd #RareDiseases #ChasingMiracles

The European Commission has approved an indication extension in the European Union for our Meningococcal Group A, C, W and Y conjugate vaccine to include use in infants from as young as 6 weeks of age to help protect against invasive meningococcal disease. Read our press release: http://spkl.io/60427z52s